Episode summary
Bloomberg Businessweek Daily Podcast: CoreWeave Triggers Rally
Bloomberg Businessweek Daily
· · 29 min · Hosts: Carol Massar, Tim Stenovec · Guests: Brody Ford, Bailey Lipschultz, Jenny Rooke
Summary
CoreWeave’s earnings and financing update sparked a sharp relief rally across the “neo cloud” group, with the host and an analyst saying investors were reacting less to the company’s still-heavy leverage than to signs it can raise money through customer prepayments and vendor financing instead of relying on the unsecured debt market. The discussion stressed that CoreWeave remains far below last year’s highs, but that the report eased fears about how it will fund the buildout needed to meet demand.
The conversation then turned to Anthropic’s planned IPO, which the host and an IPO reporter said was already multiple times oversubscribed, with bankers reportedly considering a valuation of $1.5 trillion or more. They argued that strong appetite across large asset managers, hedge funds, and retail channels could let Anthropic raise more capital now, though the final valuation and share count still depend on market conditions and Nvidia’s upcoming earnings.
Later, the host and Jenny Rooke of Genoa Ventures broadened the lens to biotech. She argued that AI is already improving drug discovery, clinical workflows, and data analysis, while government funding, FDA functionality, and U.S.-China competition remain crucial to scientific leadership. She also said the most important biotech moats may come from high-quality data, better execution, and faster translation from research to products.
Key takeaways
- The analyst said CoreWeave’s rally was driven by relief that the company can use customer prepayments and vendor financing instead of leaning immediately on unsecured debt.
- CoreWeave is still more than 66% below last year’s highs, so the move reflects sentiment repair rather than a full rerating, the analyst said.
- The IPO reporter said Anthropic is already more oversubscribed than SpaceX was at a similar stage, supporting the case for a richer valuation.
- Jenny Rooke argued that AI is speeding biotech workflows, especially by helping firms move more projects through the pipeline.
- Rooke said U.S. science depends on stable NIH funding and a functional FDA, even as China remains a serious competitor in biotech and manufacturing.
Notable quotes
“We have been having a lot of apocalyptic type fears toward the NIO clouds in the last couple of weeks”
“We're going to be able to get customer prepayment, be able to get vendor financing”
“more oversubscribed than space was at this point”
“I think one of the the quiet successes that's happening, that's maybe harder right now to, uh, to take a headline is the efficiencies”
“The reality is, is a mixed story”
How the episode opens
This is Bloomberg Businessweek daily reporting from the magazine that helps global leaders stay ahead with insight on the people, companies, and trends shaping today's complex economy, plus global business, finance and tech news as it happens. The Bloomberg Businessweek daily podcast with Carol Massar and Tim Stanback. We're going to kick it off with Brody Brody, of course, as Bloomberg News tech reporter out our San Francisco news bureau with what was in that core.
We've earnings that have made investors breathe a sigh of relief. Brody, good to have you here. What part of that report was so important to investors that they are rushing into shares of Core?
We've rushing into, uh, other NIO clouds, rushing into almost anything I related today. Yeah. Thank you for having me.
We have been having a lot of apocalyptic type fears toward the NIO clouds in the last couple of weeks. And so when they came out and said that we have a couple of different ways to raise funds, we're not going to be hitting the unsecured debt market. We're going to be able to get customer prepayment, be able to get vendor financing.
This is what really helped made people feel better about the situation. Brody but if you go back and look at just core, we've since it went public. I mean, this is a company that's still down more than 66% from the highs of last year.
Even with today's 25% increase, when you zoom out on the chart, I mean, it's climbing a hill, but it's at the bottom of that hill. These are really volatile companies. I mean, the Neo Cloud's just as a recap, they have made their business on the compute shortage, saying that we can get an Nvidia chip allocation.
We can get the data centers built very quickly.
From the episode’s captions: roughly the first two minutes, lightly cleaned. Keep watching on YouTube →
Topics
- emerging-market stocks
- ai spending
- chipmakers strength
- coreweave revenue outlook
- anthropic ipo demand signals
Companies and tickers mentioned
- CoreWeave
- Anthropic
Watch the episode
Watch “Bloomberg Businessweek Daily Podcast: CoreWeave Triggers Rally” on YouTube
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from Bloomberg Businessweek Daily
-
Bloomberg Businessweek Weekend - November 13th, 2026 | Bloomberg Businessweek -
Inside Jensen Huang’s Final Hours as Nvidia CEO | Bloomberg Businessweek -
Jensen Huang's Exit Kicks Off Nvidia Strategy Reset | Bloomberg Businessweek -
Special Episode: Bobby Jain on Why He Chose Millennium Again | Bloomberg Businessweek -
Bloomberg Businessweek Daily Podcast: Jensen’s Nvidia Departure -
Take-Two Releasing Long-Awaited Grand Theft Auto VI Next Week | Bloomberg Businessweek
Bloomberg Businessweek Daily, this episode and its artwork belong to Bloomberg. Octagon is not affiliated with the show; this page is an independent summary.
